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Abstract
Background—Pediatric studies examining the association between obstructive sleep apnea 
(OSA) and insulin sensitivity/cardiometabolic risk are limited and conflicting.
Objective—To determine if cardiometabolic risk markers are increased among obese youth with 
obstructive sleep apnea as compared with their equally obese peers without OSA.
Methods—We performed a retrospective analysis of 96 patients (age 14.2 ± 1.4 years) who 
underwent polysomnography for suspected OSA. Fasting lipids, glucose, insulin, and hemoglobin 
A1c (HbA1c) were performed as part of routine clinical evaluation. Patients were categorized into 
two groups by degree of OSA as measured by the apnea hypopnea index (AHI): none or mild 
OSA (AHI < 5) and moderate or severe OSA (AHI ≥ 5).
Results—Despite similar degrees of obesity, patients with moderate or severe OSA had higher 
fasting insulin (p = 0.037) and homeostasis model assessment-insulin resistance [HOMA-IR (p = 
0.0497)], as compared with those with mild or no OSA. After controlling for body mass index, 
there was a positive association between the AHI and log HOMA-IR (p = 0.005). There was a 
positive relationship between arousals plus awakenings during the polysomnography and fasting 
triglycerides.
Conclusions—OSA is linked with greater cardiometabolic risk markers in obese youth.
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Introduction
Obstructive sleep apnea (OSA) is associated with obesity in children and adolescents, and 
the degree of OSA is positively related to levels of visceral fat (1–4). In adults, OSA is 
linked not only to obesity and insulin resistance, but also to a high prevalence of 
cardiovascular disease (5, 6) and type 2 diabetes (7–9). However, pediatric studies 
examining the association between OSA and measures of cardiometabolic risk are very 
limited and conflicting. Some studies have shown a negative relationship between the degree 
of OSA and fasting markers of insulin sensitivity [higher fasting insulin levels and 
homeostasis model assessment-insulin resistance (HOMA-IR)] (10, 11), while others have 
shown no association between OSA and these measures or with hemoglobin A1c (HbA1c) 
among normal weight and obese children (12–14). Nevertheless, increasing awareness of the 
association between OSA and cardiometabolic disease and type 2 diabetes risk in adults has 
led to more obese youth being referred for sleep evaluation.
To evaluate the hypothesis that OSA is associated with decreased fasting insulin sensitivity 
and increased cardiometabolic risk markers in obese youth, we performed a retrospective 
analysis of clinical data from patients referred for evaluation of suspected obesity-related 
OSA. Specific aims included determining the associations between OSA measured during 
overnight polysomnography (PSG) and 1) fasting markers of insulin sensitivity (fasting 
insulin and HOMA-IR), and 2) cardiovascular risk factors (fasting lipid profile, blood 
pressure) performed during clinical evaluation.
Methods
The study was approved by the Indiana University Institutional Review Board. Clinical data 
were obtained from medical records of patients who presented for evaluation and treatment 
of obesity at the Pediatric Overweight Education and Research (POWER) Program at Riley 
Hospital for Children at Indiana University Health between January 2009 and November 
2011 and were subsequently referred for PSG. The POWER Program is a referral clinic that 
treats pediatric patients who are obese [body mass index (BMI) ≥95% for age and sex; BMI 
≥85% with complications associated with obesity]. Routine assessment at the initial visit 
consisted of history and physical examination, anthropometric measures, as well as 
laboratory evaluation including fasting lipids, liver enzymes, glucose, insulin, and HbA1c. 
Criteria warranting referral for PSG included parental concern of OSA or complaints of 
snoring accompanied by excessive daytime sleepiness, morning headache, and/or behavioral 
problems suspected to be related to sleep disruption. Tonsillar or adenoid hypertrophy, 
neuromuscular disease, and craniofacial abnormalities were not noted. One patient was 
referred to otolaryngology after an abnormal sleep study. Because pre-pubertal children 
have different metabolic profiles compared with adolescent children, we limited the analysis 
to patients aged 12 to 16 years to minimize the number of pre-pubertal adolescents included 
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in the analyses, as Tanner staging was not uniformly available. The final analysis was based 
on data from 96 patients, all of whom were obese and had complete sleep data. Fasting 
glucose was missing for 3 patients.
Patients had overnight PSG performed under the direction of the Riley Hospital for Children 
at IU Health Sleep Disorders Center using the American Academy of Sleep Medicine 
(AASM) guidelines for sleep assessment in children and adolescents. The PSGs were 
performed as part of a clinical evaluation; they were interpreted by one of three sleep 
medicine physicians. PSG data were recorded using the Sandman Elite 9.1 sleep diagnostic 
software, and applying the following EEG montage: F3M2, F4M1, C3M2, C4M1, O2M1, 
O1M2, L-EOG, R-EOG, chin EMG, limb EMG, and the following cardiorespiratory 
parameters: SpO2 and pulse (Masimo), ETCO2 (Microstream NPB 70 and Capnograph 
Sleep by BCI), nasal pressure, airflow (nasal or oral thermistor), thoracic and abdominal 
excursion (uncalibrated respirator inductance plethysmography), pulse and ECG. The apnea-
hypopnea index (AHI), which is the total number of obstructive apnea and hypopnea events 
per one hour of sleep, was calculated following the AASM manual for scoring guidelines 
(15).
Laboratory measures were performed in the Indiana University Health pathology lab. 
Plasma glucose was measured by the Beckman Coulter DXC 800 using the glucose 
hexokinase method (CV 2%). HbA1c was quantified by the Tosoh G7 ion exchange column 
using the high-performance liquid chromatography method (CV 0.3%). Plasma insulin was 
determined by the Beckman Coulter DXI 800 using a chemiluminescent sandwich assay 
(CV 6%). Fasting lipid profile was measured using the Beckman Coulter DXC 800. 
Homeostasis model assessment of insulin resistance (HOMA-IR) was calculated to express 
basal insulin resistance (16).
Patient characteristics were summarized using sample mean and standard deviation for 
continuous variables, and frequency and proportion for categorical variables. We 
dichotomized the patients into AHI classes: none or mild OSA (AHI < 5) and moderate or 
severe OSA (AHI ≥5) based on clinically accepted cut-offs for significant OSA. Two 
sample t-tests were used to compare normally distributed continuous variables between AHI 
groups and Mann-Whitney U tests were used for non-normally distributed continuous 
variables. For comparison of categorical variables, Pearson’s Chi-squared test or Fisher’s 
exact test was used. Spearman correlation coefficients were calculated between sleep 
parameters and cardiometabolic measures. Linear regression models were used to assess the 
associations between AHI and other measures of sleep disruption (arousals, awakenings, 
SaO2, ETCO2) and glucose, insulin, and lipid measures while adjusting for the effects of 
gender, race, age, and BMI. Natural logarithmic transformation was performed on HOMA-
IR, fasting insulin, and triglycerides to accommodate the right skewness of the observed 
data. Linear regression models were used to assess the interactions between the AHI and 
gender, race, age, and BMI. R software was used to perform all statistical analysis. P values 
less than 0.05 were considered statistically significant.
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Characteristics of the study population are shown in Table 1. Of the 96 patients aged 12–16 
years who reported symptoms associated with OSA, 80 (83.3%) had either mild or no OSA 
on overnight PSG and 16 patients (16.7%) had moderate or severe OSA (AHI ≥5). The 
study included 3 patients with a diagnosis of diabetes, 2 of whom were being treated (1 each 
with insulin and metformin). There were 27 patients found to have impaired fasting glucose 
by American Diabetes Association criteria. While no patients were on medications for 
hypertension or hyperlipidemia, 1 patient had a prior diagnosis of hypertension and 3 had a 
diagnosis of hyperlipidemia. In the group with the lowest AHIs, 60 (62.5%) had no OSA 
indicated by an AHI <1.5 and 20 (20.8%) had mild OSA indicated by an AHI between 1.5 
and 4.9. Nine patients (9.4%) had moderate OSA (AHI 5 – 9.9) and 7 (7.3%) had more 
severe OSA (AHI > 9.9). Significantly more males had either moderate or severe OSA as 
compared with females (p = 0.02), despite similar degrees of obesity. There were no 
significant racial differences between the groups. Blood pressure, BMI, and HbA1c did not 
differ between the 2 groups. There were significant between-group differences in fasting 
insulin (p = 0.016, Figure 1), HOMA-IR (p = 0.038, Figure 1), and triglycerides (p = 0.016) 
with higher values seen in those with moderate or severe OSA. No such association was 
seen with cholesterol, hemoglobin, or liver transaminases (AST/ALT).
Spearman correlation analysis showed a significant relationship between AHI and insulin /
HOMA-IR (r = 0.28, p = 0.006/r = 0.26, p = 0.01) and between triglyceride levels and 
arousals plus awakenings (r = 0.26, p = 0.01). However, after correcting for BMI, race, and 
age the only significant association was between triglyceride levels and arousals plus 
awakenings (regression coefficient = 0.23, p = 0.03). After controlling for the effects of 
BMI, a significant positive association existed between the AHI and log HOMA-IR (p = 
0.004, R2 with AHI = 0.19, R2 without AHI = 0.12, Table 2). Similarly, higher AHI was 
associated with higher fasting insulin levels (p = 0.001, R2 with AHI = 0.2, R2 without AHI 
= 0.1, Table 3). The association of AHI with log HOMA-IR scores was greatest among 
Hispanic patients (p = 0.043).
Discussion
In this retrospective study of patients undergoing evaluation in a clinical pediatric obesity 
program, we found that obese youth (aged 12 –16 years) with greater degrees of OSA 
characterized by higher AHI, have lower fasting insulin sensitivity (higher fasting insulin 
and HOMA-IR values) compared with equally obese peers with mild or no OSA. After 
controlling for confounding factors, including BMI, the degree of OSA was significantly 
positively associated with both fasting insulin and HOMA-IR levels. We also found an 
association between triglyceride levels and arousals plus awakenings while controlling for 
BMI, age, and race. This finding is consistent with the elevated triglyceride levels that can 
be seen with lower insulin sensitivity (17).
As has been previously reported, males were more likely than females to have significant 
OSA (18); however the degree of obesity was not significantly related to the degree of OSA 
in males. Associations between OSA and markers of cardiometabolic risk appear strongest 
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among Hispanic male youth; however, the number of Hispanic youth in the study was very 
limited and so further study will be needed to confirm this finding. Overall, these findings 
support our hypothesis that OSA is associated with increased insulin resistance in obese 
non-diabetic youth.
This is one of few studies addressing race/ethnicity differences in obesity-related OSA, and 
is the only pediatric study we are aware of to compare race-related differences in OSA and 
obesity associated cardiometabolic risk markers. Our study population included white, 
black, and Hispanic youth who were referred for sleep evaluation due to symptoms of OSA 
(parental concern of OSA or complaints of snoring together with excessive daytime 
sleepiness, morning headache, and/or behavioral problems suspected to be related to sleep 
disruption). Overall, the percentage of these youth found to have OSA on overnight PSG 
was small. This is consistent with prior findings that symptoms, such as daytime somnolence 
and snoring, do not reliably identify patients with OSA in this population (19). The majority 
of the study population was black or white and there were no differences in the prevalence 
of OSA between these two races, nor was there a race effect on the association between 
HOMA-IR or fasting insulin and AHI in blacks or whites. However 29% of all males (11 of 
38) and 40% of Hispanic males (2 of 5) who reported symptoms of impaired sleep and 
completed overnight PSG had either moderate or severe OSA. This suggests that obese male 
youth may be at increased risk for OSA as compared with obese female youth. We did not 
evaluate for PCOS, which has been shown to be associated with OSA in females (20). Our 
data is in agreement with the Multi-Ethnic Study of Atherosclerosis performed in adults, 
which collected self-reported sleep measures and found that Hispanics had a higher rate of 
OSA than whites (either prior diagnosis of OSA or symptoms 3 or more nights a week) (21). 
A prior family study to evaluate sleep disordered breathing in blacks versus whites did 
include children as young as 2 years of age and found that black participants <25 years old 
had more apneic events as compared with whites, though the clinical significance of this 
finding is not known (22). Our findings indicate that further work is needed to address race/
ethnicity determinants of OSA and associated cardiometabolic risk in youth, especially 
among males.
While other studies in children with varying BMIs undergoing sleep evaluation have shown 
obesity to be the primary determinant of insulin sensitivity rather than the degree of OSA 
(11, 13), studies in adults have shown OSA to be associated with insulin resistance, 
independent of BMI (7). A strength of our study is the inclusion of only obese youth. While 
there is clearly an association between BMI and OSA in the pediatric population as a whole, 
there were no such associations in this study population because of the severity of obesity in 
the population. Because there were no between group differences in BMI according to level 
of OSA (mild and moderate or severe), this allowed for the examination of associations 
between the degree of OSA and cardiometabolic risk factors without the confounding 
associations between obesity and OSA. As expected, BMI was associated with fasting 
insulin and HOMA-IR, thus we controlled for BMI when evaluating associations between 
the AHI and measures of fasting insulin sensitivity and cardiovascular risk. Previous studies 
performed in youth have shown an association between the AHI and HOMA-IR (10); while 
this relationship has not been significant in other pediatric studies (13, 14). This is likely 
because of smaller numbers of patients and the inclusion of non-obese patients, as the degree 
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of obesity is a significant confounder. Our findings add to the evidence that there is a 
significant association between OSA, fasting insulin sensitivity and cardiometabolic risk 
markers not only among obese adults but in the obese adolescent population as well. While 
prior studies in adult populations have also shown a strong association between OSA and 
type 2 diabetes (9, 23), there are no published pediatric studies reporting whether or not type 
2 diabetes and OSA are linked in youth. Our findings indicate that this is an area deserving 
of further research to determine whether or not similar associations exist in youth.
There are limitations associated with this study that must be noted. Because of the 
retrospective, clinical nature of the current study, it is not possible to draw conclusions with 
regard to mechanistic pathways for the relationship between the degree of OSA and 
cardiometabolic risk factors. Moreover, there were no uniform measures of glucose 
tolerance other than fasting laboratory values utilized for clinical purposes available for 
analysis. Further prospective studies including more sensitive measures of glucose tolerance, 
insulin sensitivity, markers of inflammation and measurements of visceral adiposity will 
allow for mechanistic questions to be addressed. While no patients were noted to have 
tonsillar or adenoid hypertrophy, neuromuscular disease, or other craniofacial abnormalities 
associated with obstructive sleep apnea, prospective work would allow exclusion of patients 
with these potential confounding conditions. Because of the lack of uniform documentation 
of pubertal staging from the clinical records, we used age as a surrogate marker of pubertal 
status and limited the analysis to patients who were between 12 and 16 years of age. Due to 
the differences in glucose metabolism in pre-pubertal and adolescent children, future 
prospective work should take pubertal status into account. Finally, because of referral bias 
associated with the study of specialty clinic patients, the results cannot be generalized to the 
broader pediatric population without further study.
In conclusion, obese adolescents with OSA characterized by higher arousals, awakenings, 
and AHI during PSG show evidence of worse fasting cardiometabolic profiles, including 
higher triglyceride, fasting insulin and HOMA-IR levels, compared with their equally obese 
peers who do not have clinically significant OSA. A preliminary finding that deserves more 
study is that fasting insulin and HOMA-IR may be especially linked with OSA among obese 
male Hispanic adolescents, suggesting that indications for further evaluation for symptoms 
of OSA not only vary by gender but also possibly by race/ethnicity. From a clinical 
perspective, the relationship between OSA and cardiometabolic abnormalities in obese 
adolescents should be considered when evaluating patients found to have OSA. From a 
research perspective, these relationships should be investigated further to determine 
physiologic mechanisms and if youth with impaired glucose tolerance or type 2 diabetes are 
at greater risk for OSA.
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What is already known about this subject
• In pediatric patients, obstructive sleep apnea is associated with adiposity, 
especially visceral adiposity.
• In adults, obstructive sleep apnea is also associated with a higher prevalence of 
cardiovascular disease and type 2 diabetes.
• There are limited and conflicting pediatric studies examining the association 
between obstructive sleep apnea and biomarkers of risk for cardiovascular 
disease and type 2 diabetes in youth.
What this study adds
• Obstructive sleep apnea is linked with greater cardiometabolic risk markers in 
obese adolescents.
• Fasting insulin and homeostasis model assessment-insulin resistance may be 
especially linked with obstructive sleep apnea among obese male Hispanic 
adolescents.
• The relationship between obstructive sleep apnea and cardiometabolic 
abnormalities in obese adolescents should be considered when evaluating 
patients found to have obstructive sleep apnea.
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Mean levels of homeostasis model assessment-insulin resistance (HOMA-IR) score and 
fasting insulin with 95% confidence intervals for the two apnea-hypopnea index (AHI) 
groups.
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Table 1
Demographic and clinical characteristics of study subjects by AHI classification
AHI <5 (n = 80) AHI ≥ 5 (n = 16) p-value
Gender 0.020*
 Male 27 (34%) 11 (7%)
 Female 53 (66%) 5 (3%)
Race 0.44
 White 33 (41%) 6 (38%)
 Black 40 (50%) 7 (44%)
 Hispanic 6 (8%) 2 (12%)
 Other 1 (1%) 1 (6%)
Age (years) 14.20 (1.45) 14.23 (1.34) 0.93
Age distribution
 Min 12.00 12.25
 Q1 13.04 13.08
 Median 13.99 14.17
 Q3 15.25 15.02
 Max 16.98 16.67
SBP (mmHg) 115.9 (12.4) 115.7 (17.0) 0.96
DBP (mmHg) 70.8 (9.6) 71.9 (10.9) 0.70
BMI (kg/m2) 40.1 (8.2) 40 (7.7) 0.96
BMI distribution
 Min 28.2 29.6
 Q1 34.6 34.5
 Median 38.3 38.7
 Q3 44 43.4
 Max 66.5 55.2
BMI SDS 2.6 (0.3) 2.6 (0.3) 0.52
BMI percentile 99.3 (0.7) 99.4 (0.5) 0.49
Fasting glucose (mg/dl) 93.7 (9.6) 93.1 (16.7) 0.89
HbA1C (%) 5.62 (0.38) 5.75 (0.37) 0.23
Fasting insulin 25.86 (15.35) 41.65 (26.98) 0.016*
Fasting Insulin distribution
 Min 4.32 8.28
 Q1 16.67 19.32
 Median 21.97 37.14
 Q3 30.71 50.72
 Max 81.00 106.20
HOMA-IR 6.01 (3.70) 9.68 (6.73) 0.038*
HOMA-IR distribution
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AHI <5 (n = 80) AHI ≥ 5 (n = 16) p-value
 Min 0.94 2.02
 Q1 3.55 4.39
 Median 5.09 8.05
 Q3 7.16 12.41
 Max 18.78 24.88
Fasting HDL (mg/dl) 38.3 (8.5) 35.6 (10.2) 0.33
Fasting LDL (mg/dl) 97.4 (26.0) 101.7 (22.9) 0.52
Cholesterol (mg/dl) 158.2 (31.5) 170.7 (32.4) 0.19
Triglycerides (mg/dl) 114.1 (85.5) 155.9 (87.7) 0.016*
Triglycerides distribution
 Min 35.0 65.0
 Q1 59.0 105.2
 Median 88.5 120.5
 Q3 134.8 185.0
 Max 627.0 397.0
Non-HDL Cholesterol (mg/dl) 119.7 (31.6) 134.7 (30.2) 0.10
AST (Units/L) 24.2 (8.8) 23.8 (5.8) 0.80
ALT (Units/L) 24.7 (14.3) 26.2 (14.5) 0.71
Hg (gm/dL) 13.29 (1.23) 13.28 (1.16) 0.97
Arousals 41.1 (27.0) 70.9 (64.0) 0.086
Awakenings 9.4 (6.9) 13.6 (8.5) 0.085
Obstructive Apneas 2.7 (2.8) 15.9 (17.7) <0.001*
Obstructive Apneas distribution
 Min 0.0 1.0
 Q1 1.0 3.5
 Median 2.0 12.0
 Q3 4.0 18.5
 Max 18.0 71.0
Hypopneas 2.1 (6.0) 19.5 (25.5) 0.028*
Hypopneas distribution
 Min 0.0 0.0
 Q1 0.0 0.0
 Median 0.0 0.0
 Q3 1.0 38.5
 Max 31.0 67.0
ETCO2 mean 42.9 (5.0) 42.8 (2.5) 0.96
ETCO2 max 51.3 (4.6) 53.2 (3.0) 0.0496*
AHI = Apnea-hypopnea index, SBP = systolic blood pressure, DBP = diastolic blood pressure, BMI = body mass index, HbA1c = hemoglobin 
A1c, HOMA-IR = homeostasis model assessment of insulin resistance, HDL = high-density lipoprotein, LDL = low-density lipoprotein, AST = 
aspartate aminotransferase, ALT = alanine aminotransferase, ETCO2 = end-tidal carbon dioxide concentration
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Table 2
Estimated AHI effect on log HOMA-IR adjusted for sex, race, age, and BMI-Z score
Coefficient Estimate 95% CI p-value
AHI 0.033 (0.011, 0.055) 0.004*
Female sex 0.207 (−0.045, 0.460) 0.107
Black race 0.013 (−0.234, 0.261) 0.915
Hispanic Race 0.485 (0.043, 0.928) 0.032*
Other Race 0.435 (−0.377, 1.248) 0.290
Age −0.011 (−0.097, 0.074) 0.795
BMI-Z 0.600 (0.197, 1.002) 0.004*
AHI = Apnea Hypopnea Index, BMI = Body Mass Index
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Table 3
Estimated AHI effect on log fasting insulin level adjusted for sex, race, age, and BMI-Z score
Coefficient Estimate 95% CI p-value
AHI 0.035 (0.014, 0.056) 0.001*
Female sex 0.242 (0.0004, 0.484) 0.0496*
Black race −0.011 (−0.248, 0.227) 0.930
Hispanic Race 0.436 (0.013, 0.860) 0.044*
Other Race 0.363 (−0.415, 1.141) 0.356
Age −0.007 (−0.089, 0.075) 0.873
BMI-Z 0.539 (0.154, 0.923) 0.007*
AHI = Apnea-Hypopnea Index, BMI = Body Mass Index
Pediatr Obes. Author manuscript; available in PMC 2015 December 01.
